18F-前列腺特异性膜抗原-1007 PET/CT 对原发性前列腺癌的检测性能:系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究共540例患者,评估18F-PSMA-1007 PET/CT 对原发性前列腺癌的检测性能。患者水平总检出率为94%,前列腺内肿瘤 SUVmax 中位数为16(范围3.7-77.7)。经组织病理学验证,病灶水平阳性预测值为0.90,区域淋巴结转移为0.94,局限性前列腺肿瘤为0.84。
要点
- 18F-PSMA-1007 PET/CT 患者水平总检出率为94%。
- 前列腺内肿瘤 SUVmax 中位数为16(范围3.7-77.7)。
- 病灶水平阳性预测值0.90,区域淋巴结转移0.94,局限性肿瘤0.84。
核心结论
- 18F-PSMA-1007 对局限性前列腺肿瘤病灶和区域淋巴结转移的检测表现出优异性能。
- 原发性前列腺癌中局限性肿瘤的摄取接近肝脏摄取,若等于或大于肝脏摄取可考虑为可疑恶性。
研究设计与样本
- 系统综述与荟萃分析,于2021年9月30日更新检索 PubMed/MEDLINE、EMBASE 和 Cochrane Library 数据库。
- 共纳入12项研究、540例患者。
- 按患者水平计算汇总检出率,分析纳入研究的 SUVmax 中位数,并以病理为参考标准分析阳性预测值。
主要发现
- 18F-PSMA-1007 患者水平总检出率为94%。
- 前列腺内肿瘤 SUVmax 中位数为16(范围3.7-77.7)。
- 经组织病理学验证,病灶水平阳性预测值为0.90。
- 检测区域淋巴结转移的阳性预测值为0.94。
- 检测局限性前列腺肿瘤的阳性预测值为0.84。
临床怎么用
- 作者认为原发性前列腺癌中局限性肿瘤的摄取接近肝脏摄取,若等于或大于肝脏摄取可考虑为可疑恶性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple tools are now available to determine the requirement for a biopsy to diagnose prostate cancer, and PET/CT with radiolabeled prostate-specific membrane antigen (PSMA)-targeting radiotracers has been recommended for detecting primary prostate cancer. Particularly, the radiotracer 18 F-PSMA-1007 was found to be more favorable for primary tumors compared with other PSMA-targeting radiotracers because of its low clearance via the urinary tract and better image resolution. Thus, we performed a systematic review and meta-analysis to more accurately evaluate the detection performance of 18 F-PSMA-1007 PET/CT in primary prostate cancer patients. METHODS: An update on the databases of PubMed/MEDLINE, EMBASE, and Cochrane Library for comprehensive literature search was performed on September 30, 2021. The pooling detection rate was calculated on a per-patient basis. The pooling median of the SUV max was analyzed from the included studies. Furthermore, the positive predictive value of 18 F-PSMA-1007 PET/CT with pathologic lesions was analyzed using the criterion standard. RESULTS: Twelve studies (540 patients total) were included in the meta-analysis. The overall pooling detection rate of 18 F-PSMA-1007 per patient was 94%, and the pooling median of SUV max located at the intraprostate tumor was 16 (range, 3.7-77.7). The positive predictive value of 18 F-PSMA-1007 per lesion with histopathological validation was 0.90, detecting regional lymph node metastasis was 0.94, and detecting localized prostatic tumors was 0.84. CONCLUSIONS: In the current meta-analysis, we revealed the excellent performance of 18 F-PSMA-1007 to detect localized prostatic tumor lesions and regional lymph node metastasis. Moreover, the uptake of localized tumors in primary prostate cancer was nearly liver uptake and may be considered a suspicious malignancy if it was equal to or greater than the liver uptake.
引用
- Huang YT, Tseng NC, Chen YK, et al. The Detection Performance of 18 F-Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer : A Systemic Review and Meta-analysis. Clin Nucl Med. 2022. PMID: 35452013. doi:10.1097/RLU.0000000000004228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。